BRAF and cutaneous squamous cell carcinoma: However, most patients relapsed about 7 months after targeted therapy and approximately 14-26% of patients have development of secondary cutaneous squamous cell carcinoma and hyperkeratotic lesions within the first 2-3 months after BRAF inhibition [3].